InterMune starts HCV Phase III

ITMN began an open-label Phase III trial (DIRECT) of its Infergen interferon alfacon-1 plus ribavirin in 510 HCV patients who are refractory to treatment with pegylated interferon alfa-2 plus ribaviri...